{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:17:20Z","timestamp":1792124240288,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007561","name":"Chiesi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007561","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40262-025-01568-3","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:06:55Z","timestamp":1758899215000},"page":"1587-1597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["PEGylated Proteins: How Much Does Molecular Weight Matter?"],"prefix":"10.1007","volume":"64","author":[{"given":"Diego Maria Michele","family":"Fornasari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1568_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-921-1_1","volume":"899","author":"DS Dimitrov","year":"2012","unstructured":"Dimitrov DS. Therapeutic proteins. Methods Mol Biol. 2012;899:1\u201326. https:\/\/doi.org\/10.1007\/978-1-61779-921-1_1.","journal-title":"Methods Mol Biol"},{"key":"1568_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2016.05.029","volume":"40","author":"AS Hoffman","year":"2016","unstructured":"Hoffman AS. The early days of PEG and PEGylation (1970s\u20131990s). Acta Biomater. 2016;40:1\u20135. https:\/\/doi.org\/10.1016\/j.actbio.2016.05.029.","journal-title":"Acta Biomater"},{"key":"1568_CR3","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1007\/s13346-024-01608-8","volume":"14","author":"AM L\u00f3pez-Estevez","year":"2024","unstructured":"L\u00f3pez-Estevez AM, Gref R, Alonso MJ. A journey through the history of PEGylated drug delivery nanocarriers. Drug Deliv Transl Res. 2024;14:2026\u201331. https:\/\/doi.org\/10.1007\/s13346-024-01608-8.","journal-title":"Drug Deliv Transl Res"},{"key":"1568_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10600","volume":"9","author":"Y Gao","year":"2024","unstructured":"Gao Y, Joshi M, Zhao Z, Mitragotri S. Pegylated therapeutics in the clinic. Bioeng Transl Med. 2024;9:e10600. https:\/\/doi.org\/10.1002\/btm2.10600.","journal-title":"Bioeng Transl Med"},{"key":"1568_CR5","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","volume":"15","author":"BM Chen","year":"2021","unstructured":"Chen BM, Cheng TL, Roffler SR. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano. 2021;15:14022\u201348. https:\/\/doi.org\/10.1021\/acsnano.1c05922.","journal-title":"ACS Nano"},{"key":"1568_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1021\/acs.oprd.3c00428","volume":"28","author":"C Bento","year":"2024","unstructured":"Bento C, Katz M, Santos MMM, Afonso CAM. Striving for uniformity: a review on advances and challenges to achieve uniform polyethylene glycol. Org Process Res Dev. 2024;28:860\u201390. https:\/\/doi.org\/10.1021\/acs.oprd.3c00428.","journal-title":"Org Process Res Dev"},{"key":"1568_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","volume":"105","author":"PL Turecek","year":"2016","unstructured":"Turecek PL, Bossard MJ, Schoetens F, Ivens IA. Pegylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105:460\u201375. https:\/\/doi.org\/10.1016\/j.xphs.2015.11.015.","journal-title":"J Pharm Sci"},{"key":"1568_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1248\/bpb.35.280","volume":"35","author":"T Zhao","year":"2012","unstructured":"Zhao T, Cheng YN, Tan HN, et al. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice. Biol Pharm Bull. 2012;35:280\u20138. https:\/\/doi.org\/10.1248\/bpb.35.280.","journal-title":"Biol Pharm Bull"},{"key":"1568_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jconrel.2022.09.031","volume":"351","author":"M Ibrahim","year":"2022","unstructured":"Ibrahim M, Ramadan E, Elsadek NE, et al. Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of PEGylated products. J Control Release. 2022;351:215\u201330. https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.031.","journal-title":"J Control Release"},{"key":"1568_CR10","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.drudis.2014.06.002","volume":"19","author":"A Baumann","year":"2014","unstructured":"Baumann A, Tuerck D, Prabhu S, Dickmann L, Sims J. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discov Today. 2014;19:1623\u201331. https:\/\/doi.org\/10.1016\/j.drudis.2014.06.002.","journal-title":"Drug Discov Today"},{"key":"1568_CR11","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1177\/0192623315591171","volume":"43","author":"IA Ivens","year":"2015","unstructured":"Ivens IA, Achanzar W, Baumann A, et al. PEGylated biopharmaceuticals: current experience and considerations for nonclinical development. Toxicol Pathol. 2015;43:959\u201383. https:\/\/doi.org\/10.1177\/0192623315591171.","journal-title":"Toxicol Pathol"},{"key":"1568_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","volume":"22","author":"FM Veronese","year":"2008","unstructured":"Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22:315\u201329. https:\/\/doi.org\/10.2165\/00063030-200822050-00004.","journal-title":"BioDrugs"},{"key":"1568_CR13","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.2147\/DDDT.S481420","volume":"18","author":"J Gon\u00e7alves","year":"2024","unstructured":"Gon\u00e7alves J, Caliceti P. Optimizing pharmacological and immunological properties of therapeutic proteins through PEGylation: investigating key parameters and their impact. Drug Des Devel Ther. 2024;18:5041\u201362. https:\/\/doi.org\/10.2147\/DDDT.S481420.","journal-title":"Drug Des Devel Ther"},{"key":"1568_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2516.2012.02931.x","volume":"19","author":"IA Ivens","year":"2013","unstructured":"Ivens IA, Baumann A, McDonald TA, et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia. 2013;19:11\u201320. https:\/\/doi.org\/10.1111\/j.1365-2516.2012.02931.x.","journal-title":"Haemophilia"},{"key":"1568_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese FM, Pasut G. Pegylation, successful approach to drug delivery. Drug Discov Today. 2005;10:1451\u20138. https:\/\/doi.org\/10.1016\/S1359-6446(05)03575-0.","journal-title":"Drug Discov Today"},{"key":"1568_CR16","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1124\/mol.105.014910","volume":"68","author":"S Kubetzko","year":"2005","unstructured":"Kubetzko S, Sarkar CA, Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol. 2005;68:1439\u201354. https:\/\/doi.org\/10.1124\/mol.105.014910.","journal-title":"Mol Pharmacol"},{"key":"1568_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.intimp.2012.12.012","volume":"15","author":"T Gefen","year":"2013","unstructured":"Gefen T, Vaya J, Khatib S, et al. The impact of PEGylation on protein immunogenicity. Int Immunopharmacol. 2013;15:254\u20139. https:\/\/doi.org\/10.1016\/j.intimp.2012.12.012.","journal-title":"Int Immunopharmacol"},{"issue":"Suppl 4","key":"1568_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/hae.12405","volume":"20","author":"M Carcao","year":"2014","unstructured":"Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia. 2014;20(Suppl 4):99\u2013105. https:\/\/doi.org\/10.1111\/hae.12405.","journal-title":"Haemophilia"},{"key":"1568_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/JBM.S82457","volume":"7","author":"TT Wynn","year":"2016","unstructured":"Wynn TT, Gumuscu B. Potential role of a new PEGylated recombinant factor VIII for hemophilia A. J Blood Med. 2016;7:121\u20138. https:\/\/doi.org\/10.2147\/JBM.S82457.","journal-title":"J Blood Med."},{"key":"1568_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/hae.13119","volume":"23","author":"ES Mullins","year":"2017","unstructured":"Mullins ES, Stasyshyn O, Alvarez-Roman MT, et al. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia. 2017;23:238\u201346. https:\/\/doi.org\/10.1111\/hae.13119.","journal-title":"Haemophilia"},{"key":"1568_CR21","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.2147\/DDDT.S121743","volume":"12","author":"E Santagostino","year":"2018","unstructured":"Santagostino E, Mancuso ME. Glycopegylated recombinant factor IX for hemophilia B in context. Drug Des Devel Ther. 2018;12:2933\u201343. https:\/\/doi.org\/10.2147\/DDDT.S121743.","journal-title":"Drug Des Devel Ther"},{"key":"1568_CR22","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1007\/s00520-020-05603-w","volume":"28","author":"X Li","year":"2020","unstructured":"Li X, Zheng H, Yu MC, et al. Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis. Support Care Cancer. 2020;28:5085\u201397. https:\/\/doi.org\/10.1007\/s00520-020-05603-w.","journal-title":"Support Care Cancer"},{"key":"1568_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005441.pub3","volume":"2014","author":"G Hauser","year":"2014","unstructured":"Hauser G, Awad T, Brok J, et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis c. Cochrane Database Syst Rev. 2014;2014:CD005441. https:\/\/doi.org\/10.1002\/14651858.CD005441.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1568_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1053\/gast.2002.35950","volume":"123","author":"JG McHutchison","year":"2002","unstructured":"McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis c. Gastroenterology. 2002;123:1061\u20139. https:\/\/doi.org\/10.1053\/gast.2002.35950.","journal-title":"Gastroenterology"},{"key":"1568_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1177\/0192623318791801","volume":"46","author":"AR Irizarry Rovira","year":"2018","unstructured":"Irizarry Rovira AR, Bennet BM, Bolon B, et al. Scientific and regulatory policy committee points to consider: histopathologic evaluation in safety assessment studies for PEGylated pharmaceutical products. Toxicol Pathol. 2018;46:616\u201335. https:\/\/doi.org\/10.1177\/0192623318791801.","journal-title":"Toxicol Pathol"},{"key":"1568_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.894411","volume":"13","author":"A Schoenbrunn","year":"2022","unstructured":"Schoenbrunn A, Juelke K, Reipert BM, Horling F, Turecek PL. Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages. Front Immunol. 2022;13:894411. https:\/\/doi.org\/10.3389\/fimmu.2022.894411.","journal-title":"Front Immunol"},{"key":"1568_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154\u2013155","author":"GT Kozma","year":"2020","unstructured":"Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154\u2013155:163\u201375. https:\/\/doi.org\/10.1016\/j.addr.2020.07.024.","journal-title":"Adv Drug Deliv Rev"},{"key":"1568_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ebiom.2018.10.038","volume":"37","author":"S Gupta","year":"2018","unstructured":"Gupta S, Lau K, Harding CO, et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. EBioMedicine. 2018;37:366\u201373. https:\/\/doi.org\/10.1016\/j.ebiom.2018.10.038.","journal-title":"EBioMedicine"},{"key":"1568_CR29","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1016\/j.jtha.2023.07.019","volume":"21","author":"A Hillarp","year":"2023","unstructured":"Hillarp A, Holme PA, W\u00e5land EP, et al. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII. J Thromb Haemost. 2023;21:2771\u20135. https:\/\/doi.org\/10.1016\/j.jtha.2023.07.019.","journal-title":"J Thromb Haemost"},{"key":"1568_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40268-024-00481-7","volume":"24","author":"MT Reding","year":"2024","unstructured":"Reding MT, Lalezari S, Kenet G, et al. Damoctocog alfa pegol, a PEGylated B-domain deleted recombinant extended half-life factor VIII for the treatment of hemophilia a: a product review. Drugs RD. 2024;24:359\u201381. https:\/\/doi.org\/10.1007\/s40268-024-00481-7.","journal-title":"Drugs RD"},{"key":"1568_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/jnantod.2024.102163","volume":"55","author":"J Fu","year":"2024","unstructured":"Fu J, Wu E, Li G, Wang B, Zhan C. Anti-PEG antibodies: current situation and countermeasures. Nano Today. 2024;55:102163. https:\/\/doi.org\/10.1016\/jnantod.2024.102163.","journal-title":"Nano Today"},{"key":"1568_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2018.06.002","volume":"284","author":"MD McSweeney","year":"2018","unstructured":"McSweeney MD, Wessler T, Price LSL, et al. A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse. J Control Release. 2018;284:171\u20138. https:\/\/doi.org\/10.1016\/j.jconrel.2018.06.002.","journal-title":"J Control Release"},{"key":"1568_CR33","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/s0169-409x(03)00108-x","volume":"55","author":"P Caliceti","year":"2003","unstructured":"Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev. 2003;55:1261\u201377. https:\/\/doi.org\/10.1016\/s0169-409x(03)00108-x.","journal-title":"Adv Drug Deliv Rev"},{"key":"1568_CR34","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1517\/17425255.2014.967679","volume":"10","author":"X Zhang","year":"2014","unstructured":"Zhang X, Wang H, Ma Z, Wu B. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns. Expert Opin Drug Metab Toxicol. 2014;10:1691\u2013702. https:\/\/doi.org\/10.1517\/17425255.2014.967679.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1568_CR35","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1038\/s41467-024-50568-7","volume":"15","author":"K Jiang","year":"2024","unstructured":"Jiang K, Tian K, Yu Y, et al. Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin. Nat Commun. 2024;15:6136. https:\/\/doi.org\/10.1038\/s41467-024-50568-7.","journal-title":"Nat Commun"},{"key":"1568_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1177\/0192623312474726","volume":"41","author":"DG Rudmann","year":"2013","unstructured":"Rudmann DG, Alston JT, Hanson JC, Heidel S. High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol Pathol. 2013;41:970\u201383. https:\/\/doi.org\/10.1177\/0192623312474726.","journal-title":"Toxicol Pathol"},{"key":"1568_CR37","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/jps.2600830432","volume":"83","author":"T Yamaoka","year":"1994","unstructured":"Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci. 1994;83:601\u20136. https:\/\/doi.org\/10.1002\/jps.2600830432.","journal-title":"J Pharm Sci"},{"key":"1568_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","volume":"114","author":"T Kizhner","year":"2015","unstructured":"Kizhner T, Azulay Y, Hainrichson M, et al. Characterization of a chemically modified plant cell culture expressed human \u03b1-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015;114:259\u201367. https:\/\/doi.org\/10.1016\/j.ymgme.2014.08.002.","journal-title":"Mol Genet Metab"},{"key":"1568_CR39","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase 1\/2 clinical trial. J Inherit Metab Dis. 2019;42:534\u201344. https:\/\/doi.org\/10.1002\/jimd.12080.","journal-title":"J Inherit Metab Dis"},{"key":"1568_CR40","unstructured":"European Medicines Agency. Replagal. Summary of Product Characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/replagal-epar-product-information_en.pdf. Accessed 25 Sep 2024."},{"key":"1568_CR41","unstructured":"European Medicines Agency. Elfabrio. Summary of Product Characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elfabrio-epar-product-information_en.pdf. Accessed 25 Sep 2024."},{"key":"1568_CR42","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1111\/cts.13652","volume":"16","author":"YY Hon","year":"2023","unstructured":"Hon YY, Wang J, Abodakpi H, et al. Dose selection for biological enzyme replacement therapy indicated for inborn errors of metabolism. Clin Transl Sci. 2023;16:2438\u201357. https:\/\/doi.org\/10.1111\/cts.13652.","journal-title":"Clin Transl Sci"},{"key":"1568_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.omtm.2022.07.009","volume":"26","author":"M Lenders","year":"2022","unstructured":"Lenders M, Pollmann S, Terlinden M, Brand E. Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa. Mol Ther. 2022;26:323\u201330. https:\/\/doi.org\/10.1016\/j.omtm.2022.07.009.","journal-title":"Mol Ther"},{"key":"1568_CR44","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2024;61:520\u201330. https:\/\/doi.org\/10.1136\/jmg-2023-109445.","journal-title":"J Med Genet"},{"key":"1568_CR45","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/hae.13875","volume":"26","author":"A Baumann","year":"2020","unstructured":"Baumann A. PEGylated biologics in haemophilia treatment: current understanding of their long-term safety. Haemophilia. 2020;26:e11\u20133. https:\/\/doi.org\/10.1111\/hae.13875.","journal-title":"Haemophilia"},{"key":"1568_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/10717540600814402","volume":"13","author":"M Hamidi","year":"2006","unstructured":"Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006;13:399\u2013409. https:\/\/doi.org\/10.1080\/10717540600814402.","journal-title":"Drug Deliv"},{"key":"1568_CR47","unstructured":"European Medicines Agency. CHMP Safety Working Party\u2019s response to the Paediatric Committee regarding the use of PEGylated drug products in the paediatric population - Scientific guideline. 2012. https:\/\/www.ema.europa.eu\/en\/chmp-safety-working-partys-response-paediatric-committee-regarding-use-pegylated-drug-products-paediatric-population-scientific-guideline. Accessed 1 Aug 2024."},{"key":"1568_CR48","unstructured":"European Medicines Agency. Jivi. Summary of Product Characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jivi-epar-product-information_en.pdf. Accessed 25 Sep 2024."},{"key":"1568_CR49","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/cea.12760","volume":"46","author":"E Wenande","year":"2016","unstructured":"Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46:907\u201322. https:\/\/doi.org\/10.1111\/cea.12760.","journal-title":"Clin Exp Allergy"},{"issue":"93\u2013100","key":"1568_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2024.03.022","volume":"133","author":"OS Kayode","year":"2024","unstructured":"Kayode OS, Nakonechna A, Siew LQC, et al. Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study. Ann Allergy Asthma Immunol. 2024;133(93\u2013100):e4. https:\/\/doi.org\/10.1016\/j.anai.2024.03.022.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1568_CR51","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v92iS7.12384","volume":"92","author":"A Bianchi","year":"2021","unstructured":"Bianchi A, Bottau P, Calamelli E, et al. Hypersensitivity to polyethylene glycol in adults and children: an emerging challenge. Acta Biomed. 2021;92:e2021519. https:\/\/doi.org\/10.23750\/abm.v92iS7.12384.","journal-title":"Acta Biomed"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01568-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:03:27Z","timestamp":1763168607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01568-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1568"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01568-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the Funding section.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the Funder details in the Acknowledgments section.","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Medical writing and the open access publishing fee were supported by Chiesi Farmaceutici SpA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Diego Maria Michele Fornasari has no conflict of interest to declare in relation to this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Diego Maria Michele Fornasari had sole responsibility for developing the concept of this article, providing editorial direction, reviewing all drafts and approving the draft for submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}